GENE ONLINE|News &
Opinion
Blog

2021-02-05| Trials & Approvals

FDA Approval of Tepotinib Sets Stage for Merck Versus Novartis Showdown in Metastatic NSCLC Space

by Rajaneesh K. Gopinath
Share To

Following the approval of Japan’s Ministry of Health, Labour and Welfare (MHLW) in March 2020, Merck’s oral MET inhibitor, TEPMETKO (tepotinib), has now bagged a regulatory win in the US. On February 3rd, the USFDA granted accelerated approval for the drug to treat adult patients with metastatic NSCLC harboring the MET exon 14 (METex14) skipping alteration.

Lung cancer is the second most common type of cancer and the leading cause of cancer-related deaths globally. Non-small cell lung cancer (NSCLC) is the most prevalent, with around 2 million cases diagnosed each year. Among them, approximately 3% to 5% develop mutations in the mesenchymal-epithelial transition (MET) signaling pathway, including METex14 skipping alterations and MET amplifications. Such mutations are associated with aggressive tumor behavior and poor clinical prognosis.

With this approval, TEPMETKO has become the first and only once-daily oral MET inhibitor for this disease indication. The drug will be administered orally as two 225 mg tablets (450 mg).

“This approval of TEPMETKO by the FDA is an important milestone on our mission to significantly improve the treatment of cancer where MET plays a driving role,” said Danny Bar-Zohar, M.D., Global Head of Development for the Healthcare business of Merck KGaA, Darmstadt, Germany. “Our focus now is to ensure TEPMETKO is accessible to patients in the United States and fully integrated into clinical practice given the important advance it represents for indicated patients as an oral once-a-day precision medicine.”

 

Positive Trial Data

The FDA approval is a result of encouraging data observed in the ongoing VISION (NCT02864992) trial that evaluated tepotinib as a monotherapy in 152 patients suffering from NSCLC with METex14 skipping alterations. Patients in the Phase II trial were given 450 mg of TEPMETKO once daily until disease progression or unacceptable toxicity.

The primary and additional endpoints of the study were the overall response rate (ORR) and the median duration of response (DOR), respectively. Results showed that TEPMETKO demonstrated an ORR of 43% and a DOR of 10.8 months in the 69 patients who received the treatment for the first time. In the 83 previously treated patients, those stats were 43% and 11.1 months.

Some common adverse reactions include edema, fatigue, nausea, and diarrhea, to name a few. Besides, the drug can also cause interstitial lung disease, hepatotoxicity, and embryo-fetal toxicity.

 

Market Competition

TEPMETKO will go head to head with Novartis’ kinase inhibitor TABRECTA (capmatinib), which received FDA approval last May on the back of impressive data in the GEOMETRY [NCT02414139] study. However, with once-daily dosing of 450 mg, TEPMETKO might hold the edge over TABRECTA, whose recommended dosage is 400 mg orally twice daily.

Besides, three other MET-targeting TKIs, namely crizotinib (Pfizer), cabozantinib (Exelixis Inc.), and glesatinib (Mirati Therapeutics), are currently under trials for this indication. Crizotinib has already bagged FDA’s Breakthrough Therapy Designation and is already approved to treat ROS-1 Positive NSCLC.

Data from the PROFILE 1001 [NCT00585195] trial show that crizotinib registered an ORR of 32% with a median PFS of 7.3 months and median DOR of 9.1 months in NSCLC patients harboring METex14 alterations. Merck and Novartis could expect a third player in the market sooner or later if things fall in place for crizotinib.

Related Article: FDA Greenlights Pfizer’s Xalkori for a Rare Form of Non-Hodgkin Lymphoma

References

  1. https://www.prnewswire.com/news-releases/fda-approves-tepmetko-as-the-first-and-only-once-daily-oral-met-inhibitor-for-patients-with-metastatic-nsclc-with-metex14-skipping-alterations-301221542.html
  2. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer
  3. https://www.nature.com/articles/s41591-019-0716-8

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Mayo Clinic Researchers Invent Hypothesis-Driven AI for Cancer Research Breakthroughs
2024-03-14
FDA Requests for a $7.2 Billion Budget in FY 2025 for Critical Health Initiatives
2024-03-12
Wegovy Expands Its Reach: First Weight-Loss Medication Approved to Reduce Cardiovascular Risk
2024-03-11
LATEST
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top